



Biotech Daily

Wednesday April 29, 2020

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: TELIX UP 13%; OPTISCAN DOWN 7%**
- * **COCHLEAR \$50m SHARE PLAN RAISES \$220m; TOTAL \$1.1b**
- * **IMMUTEP PLACEMENT RAISES \$12m**
- * **OSPREY WINS \$2m US COVID-19 PAYCHECK PROTECTION LOAN**
- * **OSPREY RIGHTS RAISE \$10.2m OF HOPED-FOR \$15.5m**
- * **VISIONEERING: \$5m PLACEMENT; SHARE PLAN FOR \$1m MORE**
- * **ADHERIUM, MONAGHAN US SALES DEAL FOR HAILIE SENSORS**
- * **ONCOSIL REQUESTS CAPITAL RAISING TRADING HALT**
- * **G MEDICAL REQUESTS CAPITAL RAISING TRADING HALT**
- * **ALLAN GRAY REDUCES TO 17% OF IMPEDIMED**

MARKET REPORT

The Australian stock market was up 1.51 percent on Wednesday April 29, 2020, with the ASX200 up 80.3 points to 5,393.4 points. Twenty of the Biotech Daily Top 40 stocks were up, 14 fell, five traded unchanged and one was untraded. All three Big Caps fell.

Telix was the best, up 15 cents or 12.6 percent to \$1.34, with 658,446 shares traded. Uscom climbed 12.2 percent; Paradigm was up 10.95 percent; Proteomics rose 6.9 percent; Dimerix and LBT improved five percent or more; Antisense, Imugene, Osprey, Orthocell and Prescient were up four percent or more; Starpharma was up three percent; Amplia, Ellex, Genetic Signatures and Universal Biosensors rose more than two percent; Compumedics and Nanosonics were up more than one percent; with Clinuvel and Medical Developments up by less than one percent.

Optiscan led the falls, down 0.3 cents or 7.3 percent to 3.8 cents, with 254,079 shares traded. Cynata lost 6.7 percent; Alterity and Avita fell five percent or more; Kazia, Resmed and Resonance were down more than three percent; Immutep, Mesoblast, Neuren, Pharmaxis, Polynovo and Pro Medicus shed more than two percent; Cochlear and CSL were down more than one percent; with Next Science and Volpara down by less than one percent.

COCHLEAR

Cochlear says its \$50 million share purchase plan at \$140 a share “received strong support” and it has increased the offer by \$170 million to \$220 million.

Last month the Cochlear \$800 million institutional placement was oversubscribed and the company increased it to \$880 million (BD: Mar 26, 2020).

After the market closed last night, Cochlear said that 36,724 shareholders were eligible to apply for up to \$30,000 in new shares at \$140 a share, a 16.7 percent discount to the closing price on March 24, 2020, it received valid applications totaling about \$417 million from 16,651 shareholders and it exercised the discretion allowed under the offer to increase it to \$220 million.

The company said that the retail proportion of Cochlear’s ownership remained “materially unchanged on completion of the institutional placement and [share plan]”.

Cochlear said that all participating retail shareholders had received above their pro-rata allocation if they provided sufficient application monies, subject to the \$30,000 cap.

The company said that in allocating the institutional placement shares, it ensured that institutional investors received at least their pro rata allocation where they applied for it, but some institutional shareholders who were early supporters to the underwriting process received in excess of pro-rata.

Cochlear said that there was “a small number of retail shareholders with larger holdings, who are restricted by the legislated \$30,000 participation cap from receiving a pro rata allocation” and chairman Rick Holliday Smith, chief executive officer Dig Howitt and most directors were in this group of shareholders.

The company said that the placement was made “to protect Cochlear for a temporary but uncertain time frame ... driven by the extreme events caused by the global Covid-19 pandemic, including the uncertainty for elective surgeries”.

Cochlear fell \$3.17 or 1.7 percent to \$182.75 with 291,297 shares traded.

IMMUTEP

Immutep says it has raised \$12 million through a placement to professional, institutional and sophisticated investors in Australia and Hong Kong at 12.5 cents a share.

Immutep said the issue price was a 15.5 percent discount to the 15-day volume weighted average price to April 24, 2020.

The company said the funds would be used to finance its LAG-3 related immune-oncology and autoimmune disease clinical programs, including the clinical development of eftilagimod alpha, or IMP321, the cell-line development of IMP761, for research and development, manufacturing and for general corporate purposes.

Immutep said Bell Potter Securities was lead manager and book runner to the placement.

Immutep fell half a cent or 2.9 percent to 17 cents with 5.9 million shares traded.

OSPREY MEDICAL

Osprey says it has received a \$US1,325,122 (\$A2,032,395) loan under the US Paycheck Protection Program for Covid-19 relief.

Osprey said the program provided loans to US-based small businesses to provide payroll, rent and utility payments.

The company said it expected that 50 percent of the loan would be forgiven for these purposes and the remainder would be subject to a one percent interest rate, payable within two years.

Osprey was up 0.05 cents or 4.35 percent to 1.2 cents with 2.1 million shares traded.

OSPREY MEDICAL

Osprey says it has raised \$10,244,920 through a partially underwritten three-for-one renounceable entitlement offer at 1.2 cents per Chess depositary interest (CDI).

Earlier this month, Osprey said it hoped to raise up to \$15.5 million, with its largest shareholder Brandon Capital Partners taking up its entitlement for \$3,196,744 and underwriting the shortfall for up to \$4,453,692 (BD: Apr 3, 2020).

Today, the company said it received valid applications for 482,602,345 CDIs or \$5,791,228 in new CDIs, with each new CDI having an attaching unquoted exercisable at 1.4 cents each February 15, 2021.

Osprey said that it reserved the right to place the remaining shortfall of 441,648,780 shares worth \$5,299,785 within three months of the April 24, 2020 offer closing date.

VISIONEERING TECHNOLOGIES

Visioneering says it has commitments to raise \$5 million at 1.4 cents per Chess depositary interest and hopes to raise a further \$1 million through a share plan.

Visioneering said non-executive directors would use a portion of their director's fees, amounting to an aggregate of \$79,000, to subscribe for shares on the same terms as the placement, subject to shareholder approval.

The company said the issue price was at a 15 percent discount to the 15-day volume weighted average price to April 22, 2020.

Visioneering said that investors would receive one free option for every two CDIs purchased, exercisable at 2.8 cents each by June 30, 2022.

The company said the share plan record date was April 28, the offer would open on June 1 and close on June 19, 2020.

Visioneering said Thorney Investment Group had agreed to vary the conversion price of convertible notes issued by the company in July 2019 to 2.8 cents to match the exercise price of options.

The company said that the Thorney variation, the placement and the share plan were all subject to shareholder approval at its annual meeting scheduled for May 29, 2020.

Visioneering said the funds would be used for general working capital, to prepare for additional international expansion and new product launches and to complete clinical trials currently in progress.

The company said that Shaw and Partners and Aurenda Partners were joint lead managers to the placement.

Visioneering fell 0.7 cents or 30.4 percent to 1.6 cents with 10.5 million shares traded.

ADHERIUM

Adherium says it has a sales agreement with Trudell Medical US subsidiary Monaghan Medical Corp for its Hailie inhaler sensor for asthma devices in the US.

In February, Adherium said Trudell had become a substantial shareholder in the company with 89,364,179 shares or 17.98 percent (BD: Feb 4, 2020).

Today, the company said its Hailie platform would be added to Monaghan's existing platform for patient-oriented aerosol drug delivery devices and respiratory management products in the US.

Adherium was up 0.1 cents or 2.7 percent to 3.8 cents with 4.3 million shares traded.

ONCOSIL MEDICAL

Oncosil has requested a trading halt pending an announcement “for the purpose of considering, planning and executing a capital raising”.

Trading will resume on May 5, 2020 or on an earlier announcement.

Oncosil last traded at 11 cents.

G (GEVA) MEDICAL INNOVATIONS

G Medical has requested a trading halt “pending the release of an announcement regarding a capital raising”.

Trading will resume on May 1, 2020 or on an earlier announcement.

G Medical last traded at 10.5 cents.

IMPEDIMED

Allan Gray Australia says that it has reduced its substantial shareholding in Impedimed from 139,761,904 shares (18.28%) to 131,597,400 shares (17.22%).

The Sydney-based Allan Gray said that between April 17 and 24, 2020 it sold 8,164,504 shares for \$345,477 or 4.23 cents a share.

Impedimed was unchanged at 3.9 cents with 4.3 million shares traded.